Skip Navigation

A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness

Principal Investigator: Dr. Robert Cotes


  • Men and women between the age of 18 and 40 years
  • Primary diagnosis of schizophrenia, schizophreniform disorder, or bipolar I disorder
  • Have less than 10 weeks previous treatment with antipsychotics in their lifetime
  • Have a body mass index (BMI) of 18.0 to ≤ 27.0 kg/m^2
  • Agrees to use an acceptable method of contraception for the duration of the study

Purpose: This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness. Subjects will be screened at Visit 1, up to 30 days prior to randomization. At Visit 2, eligible subjects will be randomized (1:1) to ALKS 3831 or olanzapine and receive study drug for up to 12 weeks. The study will last for approximately 16 weeks. 

Compensation: $50 for each study visit

Contact: Ayesha Khan (Study Coordinator)
Phone: 404-616-0853

Website link: